4.7 Article

The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 31, Issue 28, Pages 3565-3571

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2012.44.7821

Keywords

-

Categories

Funding

  1. National Breast Cancer Foundation
  2. Cancer Institute NSW
  3. National Health and Medical Research Council (NHMRC) Australia
  4. Cancer Council of New South Wales
  5. Cancer Council of South Australia
  6. NHMRC of Australia
  7. Pfizer Australia
  8. Pfizer International
  9. Cancer Institute New South Wales
  10. NHMRC Clinical Trials Centre

Ask authors/readers for more resources

Purpose To determine the accuracy and usefulness of oncologists' estimates of survival time in individual patients with advanced cancer. Patients and Methods Twenty-one oncologists estimated the median survival of a group of identical patients for each of 114 patients with advanced cancer. Accuracy was defined by the proportions of patients with an observed survival time bounded by prespecified multiples of their estimated survival time. We expected 50% to live longer (or shorter) than their oncologist's estimate (calibration), 50% to live from half to double their estimate (typical scenario), 5% to 10% to live <= one quarter of their estimate (worst-case scenario), and 5% to 10% to live three or more times their estimate (best-case scenario). Estimates within 0.67 to 1.33 times observed survival were deemed precise. Discriminative value was assessed with Harrell's C-statistic and prognostic significance with proportional hazards regression. Results Median survival time was 11 months. Oncologists' estimates were relatively well-calibrated (61% shorter than observed), imprecise (29% from 0.67 to 1.33 times observed), and moderately discriminative (Harrell C-statistic 0.63; P = .001). The proportion of patients with an observed survival half to double their oncologist's estimate was 63%, <= one quarter of their oncologist's estimate was 6%, and three or more times their oncologist's estimate was 14%. Independent predictors of observed survival were oncologist's estimate (hazard ratio [HR] = 0.92; P = .004), dry mouth (HR = 5.1; P < .0001), alkaline phosphatase more than 101U/L (HR = 2.8; P = .0002), Karnofsky performance status <= 70 (HR = 2.3; P = .007), prostate primary (HR = 0.23; P = .002), and steroid use (HR = 2.4; P = .02). Conclusion Oncologists' estimates of survival time were relatively well-calibrated, moderately discriminative, independently associated with observed survival, and a reasonable basis for estimating worst-case, typical, and best-case scenarios for survival.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available